Name (Synonyms) | Correlation | |
---|---|---|
drug794 | Streptokinase Wiki | 0.50 |
drug80 | Ayurveda Wiki | 0.50 |
drug999 | oxygen treatment Wiki | 0.50 |
drug879 | Unfractionated heparin Wiki | 0.50 |
drug653 | Prone Wiki | 0.50 |
drug748 | Siltuximab Wiki | 0.35 |
drug208 | Colchicine Wiki | 0.22 |
drug46 | Anakinra Wiki | 0.19 |
drug854 | Tocilizumab Wiki | 0.13 |
drug360 | Hydroxychloroquine Wiki | 0.06 |
drug616 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.16 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.15 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
D018352 | Coronavirus Infections NIH | 0.11 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.11 |
D013577 | Syndrome NIH | 0.08 |
D014777 | Virus Diseases NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There are 4 clinical trials
The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome
Description: defined as the time from randomization to either an improvement of two points on a six-category ordinal scale or discharge from the hospital: Death Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized
Measure: Time to Clinical Improvement Time: at day 15Description: defined as independece from supplemental oxygen
Measure: Time to improvement in oxygenation Time: during hospital admission (up to 28 days)Description: defined by Pa02/FiO2 ratio while breading room air
Measure: Mean change in oxygenation Time: day 1, day 15 or hospital discharge, whichever is firstDescription: Clinical sign score: 0( best) - 18 (worse)
Measure: Mean change in clinical sign score between day 1 and day 7 Time: day 1, day 7 or hospital discharge, whichever is firstDescription: Clinical sign score: 0( best) - 18 (worse)
Measure: Mean change in clinical sign score between day 1 and day 15 Time: day 1, day 15 or hospital discharge, whichever is firstDescription: Clinical sign score: 0( best) - 18 (worse)
Measure: Time to clinical sign score <6 maintained for 24h Time: during hospital admission (up to 28 days)Description: SOFA score: 0 (best) - 24 (worse)
Measure: Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7 Time: Day 1, day 7or hospital discharge, whichever is firstDescription: SOFA score: 0 (best) - 24 (worse)
Measure: Mean change of SOFA score between day 1 and day 15 Time: day 1, day 15 or hospital discharge, whichever is firstDescription: NEWS2 score: 0 (best) - 24 (worse)
Measure: Mean change NEWS2 (National Early Warning) score between day 1 and day 7 Time: day 1, day 7 or hospital discharge, whichever is firstDescription: NEWS2 score: 0 (best) - 24 (worse)
Measure: Mean change NEWS2 score between day 1 and day 15 Time: day 1, day 15 or hospital discharge, whichever is firstDescription: 6-point ordinal scale: Death Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized
Measure: Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1 Time: at day 15 or hospital discharge, whichever is firstDescription: 6-point ordinal scale: Death Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized
Measure: Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6 Time: at day 15 or hospital discharge, whichever is firstDescription: defined by Hs (Hemophagocytic Syndrome) score
Measure: incidence of secondary haemophagocytic lymphohistiocytosis Time: during hospital admission (up to 28 days)Description: defined by Hs score
Measure: Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1 Time: during hospital admission (up to 28 days)Description: defined by Hs score
Measure: Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 Time: during hospital admission (up to 28 days)This study aimed to evaluate the efficacy and safety of Ayurveda in reducing symptoms of flu like illness during the Covid 19 outbreak.
Description: Time to bring down a fever (oral temperature < 37.2 ̊C)
Measure: Time to achieve afebrile Time: Change from baseline to 3rd and 7th-dayDescription: Symptoms diary card completed twice daily from Day 0 to Day 7
Measure: Severity of symptom score Time: Change from baseline to 3rd and 7th dayDescription: Patient reported improvement using 4 scale; 0-none, 1-weak, 2-medium, 3-strong
Measure: Patient reported improvement Time: Change from baseline to 3rd and 7th-dayThis study aims to determine if provider-recommended guidance on supine (on back) vs. prone (on stomach) positioning of patients testing positive for COVID-19 requiring supplemental oxygen, but not yet mechanically ventilated, improves outcomes in the inpatient setting. This study will be performed as a pragmatic clinical trial.
Description: The highest level of support on the 5th day after enrollment according to the following scale adjusted for patient status at enrollment according to the same scale and ranked by mean FIO2 within each category, as appropriate. Death ECMO Mechanical ventilation (ranked by mean FIO2) Non-invasive ventilation such as BiPAP (ranked by mean FIO2) High flow nasal cannula, e.g. Optiflow, Vapotherm or other similar device (titrated by FiO2%) (ranked by mean FIO2) Standard nasal cannula (titrated by L/min up to 15 L/min) or face mask (ranked by mean FIO2) Room air
Measure: Modified WHO Ordinal Scale Time: 5 days post-randomizationDescription: Mean FIO2 over the first 5 days
Measure: Mean FIO2 Time: First 5 days post-randomizationCOVID-19 infection is a respiratory infectious disease caused by a virus called SARS-CoV-2 . This virus is transmitted from person to person through close contacts or respiratory droplets. Symptoms usually start 4 or 5 days after exposure. Some common symptoms include fever, dry cough, feeling tired, muscle aches, and trouble breathing. Although it may affect all organs in our body, it mainly attacks our lungs' ability to help us breathe. There are currently no FDA approved medications to treat COVID-19 infection. Patients are given medications to help alleviate the symptoms. When patients are admitted to the hospital, they are given medications to reduce fever, relieve pain and supplement oxygen. In severe cases, patients are put on a ventilator, a machine designed to to support the lungs. There are a number of drugs undergoing clinical study to see if they are effective in treating the COVID-19 virus. At Maimonides Medical Center, the investigators are taking the appropriate steps to find an effective treatment for COVID-19. The COMBAT COVID-19 Pilot Study is designed for patients diagnosed with COVID-19 infection who require oxygen supplementation to be treated with colchicine to reduce the chance of needing a mechanical ventilator. Colchicine is an FDA approved medication that is used to treat inflammatory disorders such as Gout and Familial Mediterranean Fever. It has also been used to treat other inflammatory conditions such as inflammation around the heart and been demonstrated to help patients who have had an acute heart attack. Colchicine is a readily available drug which is usually well tolerated by patients. The investigators believe that colchicine may reduce the inflammation in the lungs. If so, the lungs may be able heal at a quicker pace and we hope that this may reduce the need for mechanical ventilation. The research will be a randomized trial, patient will be randomly selected to be in either the colchicine treatment group or the standard medicines group. The treatment group will receive colchicine for 14 days or until the day of discharge. The standard medicines group will receive the usual medical therapy as determined by attending physician.
Description: Percentage of patients requiring escalation of supplemental oxygen beyond low-flow nasal cannula (.8L/min)
Measure: Percentage of Patients requiring supplemental oxygen Time: 1 day to 1 month